|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/138 | |
| A61K 31/403 | |||
| A61K 31/5377 | |||
| A61K 45/06 | |||
| A61P 25/34 | |||
| A61K 9/68 | |||
| A61K 9/70 |
| (11) | Number of the document | 2665741 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12734378.8 |
| Date of filing the European patent application | 2012-01-09 | |
| (97) | Date of publication of the European application | 2013-11-27 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/020590 |
| Date | 2012-01-09 |
| (87) | Number | WO 2012/096866 |
| Date | 2012-07-19 |
| (30) | Number | Date | Country code |
| 201161431308 P | 2011-01-10 | US |
| (72) |
BOND, Richard, A., US
GLASS, Mitchell, US
|
| (73) |
Invion, Inc,
Unit 2, 120 Bluestone Circuit,, Seventeen Mile Rocks, QLD 4073,
AU
|
| (54) | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION |
| USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION |